Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics participated in the 8th annual I-HEAL Community Wellness Day in the Mississippi Delta, providing no-cost health screenings to approximately 80 attendees. The event, hosted by the Glenn Family Foundation, saw over 700 participants receive healthy food, flu shots, and health resources. Stacey Ingram from Quest emphasized the importance of the event in improving community health outcomes. The foundation has previously assisted over 7,000 food-insecure children and implemented health literacy programs, showcasing a robust commitment to community health improvement.

Quest Diagnostics (NYSE: DGX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. Eastern Time. CEO Jim Davis and CFO Sam Samad will discuss the company's performance, strategy, and market trends. The live presentation will be webcast and available on their investor relations page. An archived version will be accessible within 24 hours and remain available until February 10, 2023.

Quest Diagnostics aims to empower individuals to enhance health outcomes through diagnostic insights.

Quest Diagnostics' latest Health Trends report reveals significant issues regarding drug misuse in the U.S. based on over 20 million drug tests conducted over the past decade. In 2021, 49% of individuals tested showed evidence of prescription drug misuse. Alarmingly, polysubstance use increased to 52%, up from 33% in 2012, while amphetamine use surged 5-fold, affecting 9.2% of those tested. The report emphasizes the ongoing risk of drug misuse across various age groups, particularly among younger adults, highlighting a pressing need for early intervention and preventive care.

Quest Diagnostics (NYSE: DGX) announced a strategic laboratory collaboration with Northern Light Health to acquire its outreach laboratory business and manage nine hospital laboratories in Maine. The agreement, selected after a competitive bid, is an all-cash transaction aimed at enhancing access to diagnostic services. The collaboration will leverage Quest's advanced testing capabilities, improving patient affordability and care in the region. Completion of the deal is expected in Q1 2023, although financial details remain undisclosed.

Getlabs and Sonora Quest Laboratories have announced a collaboration enhancing patient access to at-home lab testing. Through the integration of Getlabs' API into Sonora Quest's website, patients in Phoenix and Tucson can easily schedule in-home phlebotomy appointments. This initiative aims to improve patient convenience by eliminating logistical barriers to receiving vital health tests. The API is HIPAA compliant, ensuring secure handling of personal information. The collaboration reflects both companies' commitment to utilizing innovative technology for improved patient care.

Quest Diagnostics (DGX) has secured a group purchasing agreement with Premier Inc. (PINC) for its laboratory stewardship solutions. This collaboration enables Premier members to access Quest's Lab Stewardship Enterprise at special pricing, facilitating improved healthcare delivery. The platform offers data analytics for healthcare organizations, tracking trends and identifying cost-saving opportunities. Quest aims to enhance care quality and operational efficiency as health systems face post-pandemic challenges. This agreement marks a significant enhancement in accessibility for Quest's innovative healthcare solutions.

Quest Diagnostics (NYSE: DGX) has completed its acquisition of LabCare Plus, the outreach laboratory services business of Summa Health. This acquisition enables Quest to enhance access to its extensive test menu and health plan relationships in Northeastern Ohio. Patients and physicians will benefit from improved diagnostic services and lower out-of-pocket costs. Testing will be provided by Quest’s laboratories in Twinsburg, Ohio, and Pittsburgh, Pennsylvania, serving areas previously serviced by LabCare Plus.

ConferMED has announced the provision of specialty eConsults to Federally Qualified Health Centers (FQHCs) in Texas, Maryland, Massachusetts, Florida, and Illinois, benefiting nearly 400,000 uninsured and underinsured patients. This initiative is supported by a $2.3M grant from the Quest Diagnostics Foundation as part of its Quest for Health Equity initiative. The program will enhance access to specialty care, potentially improving health outcomes for underserved communities. Fifteen health centers have already signed up, allowing primary care providers to consult with specialists across more than 40 specialties.

DermTech, Inc. (NASDAQ: DMTK) has formed an agreement with Sonora Quest Laboratories to enhance access to its non-invasive DermTech Melanoma Test in Arizona. The test, using Smart Stickers™, boasts over 99% reliability in ruling out melanoma, allowing patients to detect the disease early, significantly improving survival rates. This partnership will reduce unnecessary biopsies and healthcare costs while increasing the test's availability through Sonora Quest’s extensive provider network.